Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells

Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). In NSCLC patients, an EGFR mutation is likely to be correlated with high levels of expressi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Acta Pharmacol Sin
Autores principales: Jiang, Xiao-Ming, Xu, Yu-Lian, Huang, Mu-Yang, Zhang, Le-Le, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672073/
https://ncbi.nlm.nih.gov/pubmed/28880013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2017.123
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares